117 related articles for article (PubMed ID: 10612219)
1. Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Blohmer JU; Paepke S; Kissner L; Elling D; Fleige B; Grineisen Y; Lichtenegger W
Zentralbl Gynakol; 1999; 121(11):522-5. PubMed ID: 10612219
[TBL] [Abstract][Full Text] [Related]
2. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
[TBL] [Abstract][Full Text] [Related]
3. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
4. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
5. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
7. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
10. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
13. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
15. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
17. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
[TBL] [Abstract][Full Text] [Related]
18. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
Moliterni A; Tarenzi E; Capri G; Terenziani M; Bertuzzi A; Grasselli G; Agresti R; Piotti P; Greco M; Salvadori B; Pilotti S; Lombardi F; Valagussa P; Bonadonna G; Gianni L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-10-S17-14. PubMed ID: 9374085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
